A continuous synthesis process of dimetridazole drug substance

CN122647398APending Publication Date: 2026-08-28SHANGHAI INST OF PHARMA IND CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510236615.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-02-28
Publication Date
2026-08-28

AI Technical Summary

Technical Problem

[0009]本发明所要解决的技术问题是为了克服现有技术中地美硝唑的合成方法安全性偏低、不易操作、难以控制反应进程、双取代杂质含量不易控制的缺陷

Benefits of technology

[0068] (1) A new continuous flow process was adopted to achieve continuous synthesis of dimetridazole active pharmaceutical ingredient. This invention, by increasing the reaction solvent, effectively reduces the concentration of the reaction substrate compared to the original process, lowering the risk of explosion and facilitating large-scale production, thus offering higher operational safety. Furthermore, the original process involved longer reaction times, and if reaction quenching was not timely, disubstituted impurities could not be effectively controlled; the new process, through the advantages of continuous flow, significantly reduces reaction time and allows for timely quenching, effectively controlling the content of disubstituted impurities and improving reaction conversion rate. In addition, continuous flow avoids prolonged exposure of operators to toxic reagents such as dimethyl sulfate, protecting their health; furthermore, the overall process is green and environmentally friendly, with excellent prospects for industrial application, representing a green, environmentally friendly, and efficient method for synthesizing dimetridazole.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122647398A_ABST
    Figure CN122647398A_ABST
Patent Text Reader

Abstract

The application discloses a continuous synthesis process of dimetridazole raw medicine. The application specifically discloses a preparation method of dimetridazole, which comprises the following steps: introducing a heterogeneous suspension into a tubular reactor to prepare dimetridazole through a substitution reaction; and the heterogeneous suspension contains 2-methyl-5-nitroimidazole, dimethyl sulfate and an aromatic hydrocarbon solvent. The preparation method has one or more of the following advantages: high safety, simple operation, high yield, easy control of reaction progress, difficulty in generation of double-substituted impurities and fast reaction speed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a continuous synthesis process for dimetridazole active pharmaceutical ingredient. Background Technology

[0002] Dimetridazole (molecular formula: C5H7N3O2, CAS number: 551-92-8), also known as 1,2-dimethyl-5-nitroimidazole, is primarily used as an antibacterial drug in veterinary medicine. It is the first-line drug for the prevention and treatment of swine dysentery and can also be used as a feed additive to promote livestock and poultry growth. Its structure is as follows:

[0003]

[0004] Currently, the industrial production of demetronidazole raw materials all adopts a batch reactor, which is obtained by methylation reaction of 2-methyl-5-nitroimidazole. The main routes for the synthesis of demetronidazole are as follows: (1) In the system of using iodomethane as methylating agent and potassium carbonate as acid-binding agent, the reaction mainly generates 3-substituted isomer impurities, and the yield of demetronidazole is relatively low; (2) Using dimethyl sulfate as methylating agent and concentrated sulfuric acid as acid catalyst, the main product demetronidazole with 1-substituted isomer is mainly produced, and the reaction yield is relatively high.

[0005] Route 2 is currently the mainstream method for industrial production of demetronidazole, offering high production efficiency. However, this method has two significant problems. First, Route 2 employs a solvent-free reaction system, which simplifies the production process to some extent, but also introduces problems of high concentrations and high nitrogen content in the substrate. This high-concentration reaction environment not only increases the difficulty of operation, but more importantly, due to the high nitrogen content in the substrate, the entire reaction system poses a potential explosion risk, seriously threatening production safety.

[0006] Secondly, 2-methyl-5-nitroimidazole is prone to over-methylation during the methylation reaction with dimethyl sulfate, leading to the formation of a large number of disubstituted impurities. Furthermore, if quality control (QC) personnel fail to provide timely feedback on key data during real-time reaction monitoring, the reaction time will be prolonged and uncontrolled, further increasing the accumulation of disubstituted impurities. These adverse factors are persistent problems in the actual reaction process, difficult to avoid through conventional methods, and ultimately negatively impact both reaction yield and product quality.

[0007] The treatment of disubstituted impurities also generates a large amount of waste, polluting the environment. Furthermore, their presence means that raw materials are not fully utilized, resulting in poor atom economy, resource waste, and violating the principles of green chemistry.

[0008] Given the aforementioned defects in existing methods for synthesizing demetronidazole, there is an urgent need to develop new methods for synthesizing demetronidazole that are highly safe, easy to operate, easy to control the reaction process, less prone to generating disubstituted impurities, and have a fast reaction rate. Summary of the Invention

[0009] The technical problem to be solved by this invention is to overcome the shortcomings of existing methods for synthesizing demetronidazole, such as low safety, difficulty in operation, difficulty in controlling the reaction process, and difficulty in controlling the content of disubstituted impurities. Therefore, this invention provides a continuous synthesis process for demetronidazole active pharmaceutical ingredient, which has one or more of the following advantages: high safety, simple operation, high yield, easy control of the reaction process, low likelihood of generating disubstituted impurities, and fast reaction rate.

[0010] This invention provides a method for preparing dimetridazole, which includes the following steps:

[0011]

[0012] A heterogeneous suspension was passed into a tubular reactor and dimetridazole was prepared via a substitution reaction.

[0013] The heterogeneous suspension contains: 2-methyl-5-nitroimidazole, dimethyl sulfate and aromatic solvents.

[0014] In certain preferred embodiments of the present invention, certain conditions, operations, or materials in the preparation method of dimetridazole have the following definitions, and conditions, operations, or materials not mentioned are the same as those described in any embodiment of the present invention (hereinafter referred to as "in a certain embodiment of the present invention"). Other aspects of the present invention are referred to using the same abbreviations as this invention and will not be described in detail hereafter.

[0015] In one embodiment of the present invention, in the heterogeneous suspension, the volume-to-mass ratio of the aromatic solvent to the 2-methyl-5-nitroimidazole is 5-20 mL / g, for example, 10 mL / g or 15 mL / g.

[0016] In one embodiment of the present invention, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole in the heterogeneous suspension is 1.0-5.0, preferably 1.5-2.5, for example 1.6, 2.0 or 2.4.

[0017] In one aspect of the present invention, in the heterogeneous suspension, the aromatic solvent is a solvent containing one or more C atoms. 1-6 Alkyl-substituted benzene, preferably with one or two C atoms. 1-3 Alkyl-substituted benzene, such as toluene or o-xylene.

[0018] In one embodiment of the present invention, the heterogeneous suspension further contains concentrated sulfuric acid;

[0019] The molar ratio of the concentrated sulfuric acid to the 2-methyl-5-nitroimidazole is 0.1-0.8, preferably 0.2-0.6, for example 0.2, 0.4 or 0.6.

[0020] In one embodiment of the present invention, the heterogeneous suspension is composed of 2-methyl-5-nitroimidazole, dimethyl sulfate and an aromatic solvent; or, it is composed of 2-methyl-5-nitroimidazole, dimethyl sulfate, an aromatic solvent and concentrated sulfuric acid.

[0021] In one aspect of the present invention, the heterogeneous suspension is prepared by the following steps:

[0022] At room temperature, 2-methyl-5-nitroimidazole, dimethyl sulfate, and an aromatic solvent are stirred until homogeneous; or, at room temperature, 2-methyl-5-nitroimidazole, dimethyl sulfate, an aromatic solvent, and concentrated sulfuric acid are stirred until homogeneous.

[0023] In one embodiment of the present invention, the tubular reactor is a coil reactor;

[0024] The material of the coil reactor can be any material that does not affect the substitution reaction; the preferred material of the coil reactor is polytetrafluoroethylene.

[0025] The inner diameter of the coil reactor is preferably 0.8-3.2 mm, for example, 0.8 mm, 1.6 mm or 3.2 mm.

[0026] In one aspect of the present invention, the progress of the substitution reaction is monitored using conventional detection methods in the art (e.g., HPLC), and the reaction endpoint is generally defined as the disappearance or cessation of reaction of one of the raw materials in the reaction solution.

[0027] In one aspect of the present invention, the residence time of the heterogeneous suspension in the tubular reactor is 4 min to 1 h, for example, 4 min, 20 min, 30 min or 1 h; the "residence time of the heterogeneous suspension" is the "reaction time" in the traditional sense.

[0028] In one aspect of the present invention, the temperature of the substitution reaction is 80-150°C, preferably 100-150°C, for example 110°C, 130°C or 150°C.

[0029] In one embodiment of the invention, the substitution reaction is carried out in an air atmosphere.

[0030] In one embodiment of the present invention, the substitution reaction is carried out under normal pressure.

[0031] In one aspect of the present invention, the materials used in the substitution reaction are only those mentioned in the specification and do not involve other materials.

[0032] In one embodiment of the present invention, the preparation method of dimetridazole is carried out via any of the following steps:

[0033] Step (A): 2-methyl-5-nitroimidazole, dimethyl sulfate and aromatic solvent are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and held at 110°C for 4 min to prepare dimetridazole via a substitution reaction.

[0034] Step (B): 2-methyl-5-nitroimidazole, dimethyl sulfate, aromatic solvent and concentrated sulfuric acid are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and dimetridazole is prepared by substitution reaction at 150°C.

[0035] Preferably, in step (B), the aromatic solvent is o-xylene;

[0036] Preferably, in step (B), the residence time of the heterogeneous suspension is 1 hour;

[0037] Preferably, in step (B), the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole in the heterogeneous suspension is 1.6, 2.0, or 2.4.

[0038] Preferably, in step (B), the molar ratio of concentrated sulfuric acid to 2-methyl-5-nitroimidazole in the heterogeneous suspension is 0.4 or 0.6.

[0039] Preferably, in step (B), the volume-to-mass ratio of the aromatic solvent to the 2-methyl-5-nitroimidazole in the heterogeneous suspension is 10 mL / g or 15 mL / g.

[0040] In one embodiment of the present invention, the preparation method of dimetridazole is carried out via any of the following steps:

[0041] Step (C): 2-methyl-5-nitroimidazole, dimethyl sulfate, o-xylene and concentrated sulfuric acid are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and dimetridazole is prepared by substitution reaction at 150°C.

[0042] In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 2.0.

[0043] In the heterogeneous suspension, the molar ratio of concentrated sulfuric acid to 2-methyl-5-nitroimidazole is 0.6.

[0044] In the heterogeneous suspension, the volume-to-mass ratio of o-xylene to 2-methyl-5-nitroimidazole is 15 mL / g;

[0045] The residence time of the heterogeneous suspension is 1 hour;

[0046] The inner diameter of the coil reactor is 1.6 mm;

[0047] Step (D): 2-methyl-5-nitroimidazole, dimethyl sulfate, o-xylene and concentrated sulfuric acid are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and dimetridazole is prepared by substitution reaction at 150°C.

[0048] In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 2.4.

[0049] In the heterogeneous suspension, the molar ratio of concentrated sulfuric acid to 2-methyl-5-nitroimidazole is 0.6.

[0050] In the heterogeneous suspension, the volume-to-mass ratio of o-xylene to 2-methyl-5-nitroimidazole is 10 mL / g;

[0051] The residence time of the heterogeneous suspension is 1 hour;

[0052] The inner diameter of the coil reactor is 1.6 mm;

[0053] Step (E): 2-methyl-5-nitroimidazole, dimethyl sulfate, o-xylene and concentrated sulfuric acid are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and dimetridazole is prepared by substitution reaction at 150°C.

[0054] In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 1.6.

[0055] In the heterogeneous suspension, the molar ratio of concentrated sulfuric acid to 2-methyl-5-nitroimidazole is 0.4.

[0056] In the heterogeneous suspension, the volume-to-mass ratio of o-xylene to 2-methyl-5-nitroimidazole is 10 mL / g;

[0057] The residence time of the heterogeneous suspension is 1 hour;

[0058] The inner diameter of the coil reactor is 3.2 mm.

[0059] In one embodiment of the present invention, the method for preparing dimetridazole further includes one or more of the following post-processing steps: adjusting pH to neutral, filtering, drying and recrystallization;

[0060] The preferred method for adjusting the pH to neutral is to use concentrated ammonia solution to adjust the pH to neutral.

[0061] The drying process is preferably carried out at 70°C.

[0062] The recrystallization is preferably performed using ethanol.

[0063] Unless otherwise specified, the terms used in this invention may be defined as follows:

[0064] "Molar ratio" refers to the numerical value of the ratio of the amount of one substance to the amount of another substance. For example, "the molar ratio of the dimethyl sulfate to the 2-methyl-5-nitroimidazole is 1.0-4.0" means "the molar ratio of the dimethyl sulfate to the 2-methyl-5-nitroimidazole is (1:1)-(4:1)".

[0065] Based on common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.

[0066] The reagents and raw materials used in this invention are all commercially available.

[0067] The positive and progressive effects of this invention are as follows:

[0068] (1) A new continuous flow process was adopted to achieve continuous synthesis of dimetridazole active pharmaceutical ingredient. This invention, by increasing the reaction solvent, effectively reduces the concentration of the reaction substrate compared to the original process, lowering the risk of explosion and facilitating large-scale production, thus offering higher operational safety. Furthermore, the original process involved longer reaction times, and if reaction quenching was not timely, disubstituted impurities could not be effectively controlled; the new process, through the advantages of continuous flow, significantly reduces reaction time and allows for timely quenching, effectively controlling the content of disubstituted impurities and improving reaction conversion rate. In addition, continuous flow avoids prolonged exposure of operators to toxic reagents such as dimethyl sulfate, protecting their health; furthermore, the overall process is green and environmentally friendly, with excellent prospects for industrial application, representing a green, environmentally friendly, and efficient method for synthesizing dimetridazole.

[0069] (2) The continuous synthesis process of dimetridazole raw material provided by the present invention has one or more of the following advantages: high safety, simple operation, high yield, easy control of reaction process, less likelihood of generating disubstituted impurities and fast reaction speed. Attached Figure Description

[0070] Figure 1This is a schematic diagram of the reaction device of the present invention. Detailed Implementation

[0071] The present invention is further illustrated below by way of embodiments, but the invention is not limited to the scope of the embodiments described herein. Experimental methods in the following embodiments that do not specify specific conditions were performed according to conventional methods and conditions, or as selected according to the product instructions.

[0072] The HPLC detection conditions in Examples 1-13 and Comparative Example 1 of this invention are as follows:

[0073] Column: Octadecylsilane-bonded silica gel as the packing material;

[0074] The mobile phase consisted of potassium dihydrogen phosphate buffer (pH 3.5) and methanol;

[0075] Flow rate: 1.0 mL / min.

[0076] gradient:

[0077]

[0078] In this invention, the coil reactor is made of polytetrafluoroethylene (PTFE).

[0079] In this invention, the "analytical yield" (i.e., the content of dimetridazole in the product) and the "content of disubstituted impurities" are calculated using the following method:

[0080]

[0081] In the formula X i (%) indicates the content of the component, A i Represents the peak area of ​​the component. This represents the sum of the peak areas of all components in the sample, where n is the total number of components in the sample;

[0082] The structure of the double-substituted impurity is as follows:

[0083] Example 1:

[0084] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 4.96 g of dimethyl sulfate (1.0 eq), and 75 mL of toluene (15 VT, mL / g) at room temperature until homogeneous. The heterogeneous suspension was then pumped into a 30 mL coil reactor (0.8 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 110 °C, and the reaction residence time was 4 min. HLPC analysis showed that the yield of dimetridazole was 71.99%, and the content of disubstituted impurities was 15.12%.

[0085] Example 2:

[0086] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 9.92 g of dimethyl sulfate (2.0 eq), and 50 mL of toluene (10 VT, mL / g) at room temperature until homogeneous. The heterogeneous suspension was then pumped into a 60 mL coil reactor (1.6 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 110 °C, and the reaction residence time was 30 min. HPLC analysis showed that the yield of the product dimetridazole was 71.06%, and the content of the disubstituted impurity was 14.78%.

[0087] Example 3:

[0088] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 4.96 g of dimethyl sulfate (1.0 eq), and 50 mL of o-xylene (10 VT, mL / g) at room temperature until homogeneous. The heterogeneous suspension was then pumped into a 60 mL coil reactor (1.6 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 130 °C, and the reaction residence time was 30 min. HPLC analysis showed that the yield of the product dimetridazole was 72.67%, and the content of the disubstituted impurity was 13.72%.

[0089] Example 4:

[0090] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 9.92 g of dimethyl sulfate (2.0 eq), 0.78 g of concentrated sulfuric acid (0.2 eq), and 50 mL of o-xylene (10 VT, mL / g) at room temperature until homogeneous. The heterogeneous solution was then pumped into a 60 mL coil reactor (1.6 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 150 °C, and the reaction residence time was 30 min. HPLC analysis showed that the yield of the product dimetridazole was 75.67%, and the content of the disubstituted impurity was 13.82%.

[0091] Example 5:

[0092] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 9.92 g of dimethyl sulfate (2.0 eq), 1.57 g of concentrated sulfuric acid (0.4 eq), and 50 mL of o-xylene (10 VT, mL / g) at room temperature until homogeneous. The heterogeneous solution was then pumped into a 60 mL coil reactor (1.6 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 150 °C, and the reaction residence time was 20 min. HPLC analysis showed that the yield of the product dimetridazole was 71.57%, and the content of the disubstituted impurity was 15.72%.

[0093] Example 6:

[0094] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 9.92 g of dimethyl sulfate (2.0 eq), 2.36 g of concentrated sulfuric acid (0.6 eq), and 50 mL of o-xylene (10 VT, mL / g) at room temperature until homogeneous. The heterogeneous solution was then pumped into a 60 mL coil reactor (1.6 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 150 °C, and the reaction residence time was 20 min. HPLC analysis showed that the yield of the product dimetridazole was 67.20%, and the content of the disubstituted impurity was 15.86%.

[0095] Example 7:

[0096] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 9.92 g of dimethyl sulfate (2.0 eq), 2.36 g of concentrated sulfuric acid (0.6 eq), and 75 mL of o-xylene (15 VT, mL / g) at room temperature until homogeneous. The heterogeneous solution was then pumped into a 120 mL coil reactor (1.6 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 150 °C, and the reaction residence time was 1 h. HPLC analysis showed that the product, dimetridazole, had a yield of 81.19%, and the content of disubstituted impurities was 13.12%. Post-treatment involved adjusting the pH to neutral with concentrated ammonia, resulting in the precipitation of a large amount of product. The product was filtered, dried at 70 °C, and then recrystallized from ethanol to obtain 3.20 g of product, with a yield of 56% and a purity of 99.68%.

[0097] Example 8:

[0098] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 11.91 g of dimethyl sulfate (2.4 eq), 2.36 g of concentrated sulfuric acid (0.6 eq), and 50 mL of o-xylene (10 VT, mL / g) at room temperature until homogeneous. The heterogeneous solution was then pumped into a 120 mL coil reactor (1.6 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 150 °C, and the reaction residence time was 1 h. HPLC analysis showed that the yield of the product dimetridazole was 80.59%, and the content of the disubstituted impurity was 14.97%.

[0099] Example 9:

[0100] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 7.94 g of dimethyl sulfate (1.6 eq), 1.57 g of concentrated sulfuric acid (0.4 eq), and 50 mL of o-xylene (10 VT, mL / g) at room temperature until homogeneous. The heterogeneous solution was then pumped into a 120 mL coil reactor (1.6 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 150 °C, and the reaction residence time was 1 h. HPLC analysis showed that the yield of the product dimetridazole was 74.62%, and the content of the disubstituted impurity was 16.12%.

[0101] Example 10:

[0102] A heterogeneous suspension was prepared by stirring 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 7.94 g of dimethyl sulfate (1.6 eq), 1.57 g of concentrated sulfuric acid (0.4 eq), and 50 mL of o-xylene (10 VT, mL / g) at room temperature until homogeneous. The heterogeneous solution was then pumped into a 120 mL coil reactor (3.2 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 150 °C, and the reaction residence time was 1 h. HPLC analysis showed that the yield of the product dimetridazole was 79.52%, and the content of the disubstituted impurity was 14.67%.

[0103] Example 11:

[0104] 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 14.88 g of dimethyl sulfate (3.0 eq), and 15 mL of formic acid were stirred at room temperature to form a homogeneous solution. The homogeneous solution was then pumped into a 30 mL coil reactor (3.2 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 100 °C, and the reaction residence time was 5 min. HPLC analysis showed that the yield of the product, dimetridazole, was 36.75%.

[0105] Example 12:

[0106] 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 14.88 g of dimethyl sulfate (3.0 eq), and 15 mL of DMF were stirred at room temperature to form a homogeneous solution. The homogeneous solution was then pumped into a 30 mL coil reactor (3.2 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 100 °C, and the reaction residence time was 5 min. HPLC analysis showed that the yield of the product dimetridazole was 41.89%, and the content of the disubstituted impurities was 54.41%.

[0107] Example 13:

[0108] 5 g of 2-methyl-5-nitroimidazole (1.0 eq), 14.88 g of dimethyl sulfate (3.0 eq), and 15 mL of DMSO were stirred at room temperature to form a homogeneous solution. The homogeneous solution was then pumped into a 30 mL coil reactor (3.2 mm inner diameter) using a peristaltic pump. The reaction temperature was controlled at 100 °C, and the reaction residence time was 5 min. HPLC analysis showed that the yield of the product dimetridazole was 23.14%, and the content of the disubstituted impurity was 62.92%.

[0109] Comparative Example 1:

[0110] 0.14 g of methanol and 0.76 g of 98% sulfuric acid were added to a reaction flask and stirred until homogeneous. The mixture was heated to 35°C. First, 1.35 g of 2-methyl-5-nitroimidazole was added to the reaction flask, followed by a slow dropwise addition of 1.45 g of dimethyl sulfate. The reaction temperature was maintained at 95°C during the addition of dimethyl sulfate. After the addition of dimethyl sulfate was complete, the temperature was lowered to 80°C. Second, 2.30 g of 2-methyl-5-nitroimidazole was added to the reaction flask, followed by a slow dropwise addition of 1.92 g of dimethyl sulfate. The reaction temperature was maintained at 120°C. After the addition of dimethyl sulfate was complete, the temperature was lowered to 100°C. Third, 1.35 g of 2-methyl-5-nitroimidazole was added to the reaction flask, followed by a slow dropwise addition of 0.90 g of dimethyl sulfate. The reaction temperature was maintained at 95°C. After observing that the reaction temperature no longer rose within 5 minutes, the temperature was increased to 125°C, and the reaction was allowed to proceed for 8 hours. The yield of the product dimetridazole was 80.70% according to HPLC analysis.

Claims

1. A method for preparing dimetridazole, comprising the following steps: A heterogeneous suspension was passed into a tubular reactor and dimetridazole was prepared via a substitution reaction. The heterogeneous suspension contains: 2-methyl-5-nitroimidazole, dimethyl sulfate and aromatic solvents.

2. The preparation method according to claim 1, characterized in that, It meets one or more of the following conditions: (1) In the heterogeneous suspension, the volume-to-mass ratio of the aromatic solvent to the 2-methyl-5-nitroimidazole is 5-20 mL / g; (2) In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 1.0-5.0; (3) In the heterogeneous suspension, the aromatic solvent is formed by one or more C... 1-6 Alkyl-substituted benzene; (4) The heterogeneous suspension also contains concentrated sulfuric acid; (5) The tubular reactor is a coil reactor; (6) In the tubular reactor, the residence time of the heterogeneous suspension is 4 min-1 h; (7) The temperature of the substitution reaction is 80-150℃.

3. The preparation method according to claim 2, characterized in that, It meets one or more of the following conditions: (1) In the heterogeneous suspension, the volume-to-mass ratio of the aromatic solvent to the 2-methyl-5-nitroimidazole is 10 mL / g or 15 mL / g; (2) In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 1.5-2.5; (3) In the heterogeneous suspension, the aromatic solvent is formed by one or two C atoms. 1-3 Alkyl-substituted benzene; (4) The heterogeneous suspension also contains concentrated sulfuric acid; The molar ratio of the concentrated sulfuric acid to the 2-methyl-5-nitroimidazole is 0.1-0.8; (5) The material of the coil reactor is polytetrafluoroethylene; (6) The inner diameter of the coil reactor is 0.8-3.2 mm; (7) In the tubular reactor, the residence time of the heterogeneous suspension is 4 min, 20 min, 30 min or 1 h; (8) The temperature of the substitution reaction is 100-150℃.

4. The preparation method according to claim 3, characterized in that, It meets one or more of the following conditions: (1) In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 1.6, 2.0 or 2.4; (2) In the heterogeneous suspension, the aromatic solvent is toluene or o-xylene; (3) The heterogeneous suspension also contains concentrated sulfuric acid; The molar ratio of the concentrated sulfuric acid to the 2-methyl-5-nitroimidazole is 0.2, 0.4, or 0.

6. (4) The inner diameter of the coil reactor is 0.8 mm, 1.6 mm or 3.2 mm; (5) The temperature of the substitution reaction is 110℃, 130℃ or 150℃.

5. The preparation method according to claim 1, characterized in that, The heterogeneous suspension is composed of 2-methyl-5-nitroimidazole, dimethyl sulfate and aromatic solvents; Alternatively, the heterogeneous suspension may be composed of 2-methyl-5-nitroimidazole, dimethyl sulfate, aromatic solvents, and concentrated sulfuric acid.

6. The preparation method according to claim 5, characterized in that, The heterogeneous suspension was prepared by the following steps: 2-methyl-5-nitroimidazole, dimethyl sulfate and an aromatic solvent were stirred evenly at room temperature; Alternatively, the heterogeneous suspension is prepared by the following steps: at room temperature, 2-methyl-5-nitroimidazole, dimethyl sulfate, an aromatic solvent and concentrated sulfuric acid are stirred until homogeneous.

7. The preparation method according to claim 1, characterized in that, The preparation method of the aforementioned dimetridazole is carried out via any of the following steps: Step (A): 2-methyl-5-nitroimidazole, dimethyl sulfate and aromatic solvent are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and held at 110°C for 4 min to prepare dimetridazole via a substitution reaction. Step (B): 2-methyl-5-nitroimidazole, dimethyl sulfate, aromatic solvent and concentrated sulfuric acid are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and dimetridazole is prepared by substitution reaction at 150°C.

8. The preparation method according to claim 7, characterized in that, It meets one or more of the following conditions: (1) In step (B), the aromatic solvent is o-xylene; (2) In step (B), the residence time of the heterogeneous suspension is 1 hour; (3) In step (B), the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole in the heterogeneous suspension is 1.6, 2.0 or 2.

4. (4) In step (B), the molar ratio of concentrated sulfuric acid to 2-methyl-5-nitroimidazole in the heterogeneous suspension is 0.4 or 0.

6. (5) In step (B), the volume-to-mass ratio of the aromatic solvent to the 2-methyl-5-nitroimidazole in the heterogeneous suspension is 10 mL / g or 15 mL / g.

9. The preparation method according to claim 1, characterized in that, The preparation method of the aforementioned dimetridazole is carried out via any of the following steps: Step (C): 2-methyl-5-nitroimidazole, dimethyl sulfate, o-xylene and concentrated sulfuric acid are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and dimetridazole is prepared by substitution reaction at 150°C. In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 2.

0. In the heterogeneous suspension, the molar ratio of concentrated sulfuric acid to 2-methyl-5-nitroimidazole is 0.

6. In the heterogeneous suspension, the volume-to-mass ratio of o-xylene to 2-methyl-5-nitroimidazole is 15 mL / g; The residence time of the heterogeneous suspension is 1 hour; The inner diameter of the coil reactor is 1.6 mm; Step (D): 2-methyl-5-nitroimidazole, dimethyl sulfate, o-xylene and concentrated sulfuric acid are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and dimetridazole is prepared by substitution reaction at 150°C. In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 2.

4. In the heterogeneous suspension, the molar ratio of concentrated sulfuric acid to 2-methyl-5-nitroimidazole is 0.

6. In the heterogeneous suspension, the volume-to-mass ratio of o-xylene to 2-methyl-5-nitroimidazole is 10 mL / g; The residence time of the heterogeneous suspension is 1 hour; The inner diameter of the coil reactor is 1.6 mm; Step (E): 2-methyl-5-nitroimidazole, dimethyl sulfate, o-xylene and concentrated sulfuric acid are stirred evenly at room temperature to prepare a heterogeneous suspension. The heterogeneous suspension is passed into a coil reactor and dimetridazole is prepared by substitution reaction at 150°C. In the heterogeneous suspension, the molar ratio of dimethyl sulfate to 2-methyl-5-nitroimidazole is 1.

6. In the heterogeneous suspension, the molar ratio of concentrated sulfuric acid to 2-methyl-5-nitroimidazole is 0.

4. In the heterogeneous suspension, the volume-to-mass ratio of o-xylene to 2-methyl-5-nitroimidazole is 10 mL / g; The residence time of the heterogeneous suspension is 1 hour; The inner diameter of the coil reactor is 3.2 mm.

10. The preparation method according to claim 1, characterized in that, The method for preparing dimetridazole further includes one or more of the following post-processing steps: adjusting pH to neutral, filtering, drying, and recrystallization; The pH adjustment to neutral is achieved by using concentrated ammonia solution to adjust the pH to neutral. The drying process is carried out at 70°C. The recrystallization is performed using ethanol.